PolicyWinds
Topic and direction labels are AI-assisted, and each one quotes the bill text it is based on. How labels work
New York · 2025-2026 General Assembly

S08544 Provides that the prescribing, dispensing, or receipt of mifepristone or any drug used for medication abortion shall not be considered a criminal conversion act under certain circumstances; provides that mifepristone or any drug used for medication abortion shall not be deemed to be adulterated or misbranded under certain circumstances.

Direction

Abortion medication abortionAI label

Expands abortion access model confidence 90%

Protects the prescribing, dispensing, or receipt of mifepristone or other medication abortion drugs from being treated as criminal diversion, adulterated, or misbranded under state law even if no longer FDA-approved or bearing current labeling, so more legal access to medication abortion.

The prescribing, dispensing, or receipt of brand name or generic mifepristone or any drug used for medication abortion shall not be considered a criminal diversion act for purposes of this definition solely because it is no longer approved by the federal food and drug administration or because it no longer bears the label currently in effect, provided that: (i) its labeling was true and accurate at the time of manufacture; and (ii) the drug is recommended for the purpose for which it was prescribed under World Health Organization guidelines that are current at the time of prescribing or_disp.

✓ Quote verified word for word in the bill text

  1. Filed (completed)
  2. Committee (completed)
  3. Passed one chamber
  4. Passed both
  5. Governor
  6. Law

Status: Died (session ended)

Last action
2026-01-28: returned to senate
Filed
2025-10-24
Sponsor
Michelle Hinchey D + 5 cosponsors (5 D)

Why the model tagged it this way: The bill amends state penal and education laws to shield mifepristone and other medication abortion drugs from certain criminal and regulatory restrictions tied to FDA approval or labeling status, provided labeling was accurate at manufacture and use follows current WHO guidelines. This expands legal access to medication abortion by protecting its prescribing, dispensing, and receipt from being treated as diversion, adulteration, or misbranding. No other listed topics are substantively addressed.

Related bills

Hearings and calendar

Votes

DateChamberMotionYea-Nay
2026-01-20SSenate Rules Committee Vote13-6Passed
2026-01-27SSenate Floor Vote - Final Passage37-21Passed
2026-01-28AAssembly Floor Vote - Final Passage94-48Passed

Sponsors

Text versions

History (11 actions)
DateChamberAction
2026-01-28Areturned to senate
2026-01-28Apassed assembly
2026-01-28Aordered to third reading cal.241
2026-01-28Asubstituted for a9217
2026-01-27Areferred to codes
2026-01-27SDELIVERED TO ASSEMBLY
2026-01-27SPASSED SENATE
2026-01-20SORDERED TO THIRD READING CAL.59
2026-01-20SCOMMITTEE DISCHARGED AND COMMITTED TO RULES
2026-01-07SREFERRED TO CODES
2025-10-24SREFERRED TO RULES